SEC Filing | BioNTech

View:

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Tureci Ozlem

(Last)

(First)

(Middle)

C/O BIONTECH SE

AN DER GOLDGRUBE 12

(Street)

MAINZ

D-55131

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
BioNTech SE [ BNTX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
	Officer (give title below)	Other (specify below)
Chief Medical Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Option (right to buy)	05/22/2027⁽¹⁾	05/22/2033	Ordinary Shares⁽²⁾	18,416	113.94⁽³⁾	D
Option (right to buy)	08/26/2028⁽¹⁾	08/26/2034	Ordinary Shares⁽²⁾	25,459	⁽³⁾⁽⁴⁾	D
Option (right to buy)	05/28/2029⁽¹⁾	05/28/2035	Ordinary Shares⁽²⁾	9,306	⁽³⁾⁽⁵⁾	D
Phantom Option	05/12/2025⁽¹⁾	05/12/2031	Ordinary Shares⁽⁶⁾	7,112	185.23⁽³⁾	D
Phantom Option	05/31/2026⁽¹⁾	05/31/2032	Ordinary Shares⁽⁶⁾	14,664	152.1⁽³⁾	D
Performance Share Unit	05/27/2029⁽⁷⁾	05/27/2035	Ordinary Shares⁽⁷⁾	11,633	0	D

Explanation of Responses:

1. The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions.

2. The option may be settled in ordinary shares, American Depositary Shares ("ADSs") and/or cash at the election of the supervisory board.

3. Subject to adjustment such that the trading price of an ADS as of an exercise date does not exceed 800% of the grant date exercise price.

4. The exercise price of this option is EUR 75.91.

5. The exercise price of this option is EUR 93.35.

6. Each phantom option represents the right to receive a cash payment equal to the difference between an exercise closing price (average closing price of an ADS over the last ten trading days preceding the exercise date) and the exercise price.

7. Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney

	/s/ Humza Bokhari, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

EX-24

LIMITED POWER OF ATTORNEY

FOR SEC REPORTING OBLIGATIONS

Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Zoey Neuenschwander, Stefanie Lutze, and Humza Bokhari, signing singly and each acting individually, as the undersigned’s true and lawful attorney-in-fact with full power and authority as hereinafter described to:

(1) submit to the U.S. Securities and Exchange Commission (the “SEC”) a Form ID Application and/or Passphrase Update Application or any other application materials to enable the undersigned to gain or maintain access to the Electronic Data Gathering, Analysis and Retrieval system of the SEC;

(2) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on

behalf of the undersigned pursuant to this Limited Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion;

(3) execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or director of BioNTech SE (the “Company”), filings under Section 16 of the Securities Exchange Act of 1934, Forms 144, and Schedules 13D and 13G, each including any amendments thereto;

(4) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, complete and execute any such filings, prepare, complete and execute any amendment or amendments thereto, and timely deliver and file such form with the SEC and any stock exchange or similar authority; and

(5) seek or obtain, as the undersigned’s representative and on the undersigned’s behalf, information regarding transactions in the Company’s securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to such attorney-in-fact and approves and ratifies any such release of information.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming nor relieving, nor is the Company assuming nor relieving, any of the undersigned’s responsibilities

to comply with filing obligations pursuant to Form 144, Schedule 13D, Schedule 13G, Form 3, Form 4, or Form 5. The undersigned acknowledges that neither the Company nor the foregoing attorneys-in-fact assume (i) any liability for the undersigned’s responsibility to comply with the beneficial ownership and transaction reporting requirements associated with the foregoing filings or (ii) any liability of the undersigned for any failure to comply with such requirements.

This Limited Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file any such with respect to the undersigned’s beneficial ownership of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

[Signature page follows.]

IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to be executed as of this 25th day of February, 2026.


Mainz, 25. Feb 2026	/s/ Özlem Türeci
	Name: Özlem Türeci

File No. 974 /2026 D.

I hereby certify, that the above signature are the true signature, subscribed in my presence, of

Dr. Özlem Türeci,

born [***],

business adress: 55131 Mainz, An der Goldgrube 12

- personally known to me –

Upon my inspection of today of the commercial register, I certify that

BioNTech SE

is registered at the Municipal Court of Mainz - Commercial Register - under No. HRB 48720 and that

Dr. Özlem Türeci, born [***],

as this company's Management Board Member,

are registered with the right to jointly act as this company' s legal representatives.

Mainz, 25th of February 2026

[SEAL]

/s/ Mascha Diefenbach

Diefenbach, Notary public

26D0974.docx

APOSTILLE

(Convention de La Haye du 5 octobre 1961)

1. Country: Federal Republic of Germany

This public document

2. has been signed by Mascha Diefenbach

3. acting in the capacity of notary public

4. bears the seal/stamp of Mascha Diefenbach - Notarin in Mainz [SEAL]

Certified

5. at Mainz 6. the 27.02.2026

7. by the President of the District Court

8. No 256/2026


9. Stamp: [SEAL]	10. Signature:
	/s/ Thomas Bergmann
	Thomas Bergmann